FDA and Department of Health Address Drug Shortages - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA and Department of Health Address Drug Shortages


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA Commissioner Margaret Hamburg and US Assistant Secretary for Health Howard Koh released a statement on Sept. 9, 2011, aimed at a stakeholder meeting held at the US Department of Health and Human Services (HHS) to address the growing problem of drug shortages in the United States. The shortages affect many necessary drugs, including those for cancer, anesthesia, influenza, and other critical conditions.

In 2010, there were 178 drug shortages reported to FDA, 132 of which involved sterile injectable drugs, according the agency’s frequently asked questions website for its Drug Shortages program. So far this year, there has been “an increasing number of shortages, especially those involving older sterile injectable drugs,” according to the site.

“All parties involved in the supply of drugs to Americans have a responsibility to make sure patients have access to the drugs they need,” states an FDA press release on the subject.

The agency intends to release a report in the coming weeks that analyzes the problem and provides recommendations. “One suggestion is a mechanism for manufacturers to report impending supply disruptions and discontinuation of drugs, which could help to curb drug shortages and improve the continuity of the drug supply,” according to the press release.

“Meanwhile, the FDA will continue its efforts to work with manufacturers to ameliorate shortages. For example, FDA already expedites requests to qualify new manufacturing sites, new production lines or new raw-material suppliers to avert drug shortages. HHS remains committed to working with manufacturers, providers, patient advocates, and other stakeholders to help minimize drug shortages, protect patients, and identify solutions to this serious problem,” said the statement.

FDA will hold a public workshop on Sept. 26, 2011, in Silver Spring, Maryland, to further discuss drug shortages and the Center for Drug Evaluation and Research’s approach for addressing them. The causes and effects of drug shortages, as well as possible strategies for preventing or mitigating them, will be discussed.

 

See Related Pharm Tech Articles:

Drug Shortages Rise, but No Requirement to Report Them

Drug Shortages Encourage Gray-Market Activity

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here